Handok’s Collaborator, Compass Therapeutics, Announces Positive Topline Results from Phase 2/3 of Tovecimig (HDB001A) 2025.04.02

Handok Affiliate Rezolute's Congenital Hyperinsulinism Treatment RZ358 Designated as a Breakthrough Therapy by the FDA 2025.01.08

Handok Begins Domestic Sales of Hyperlipidemia Treatment Lipidil from Korea Abbott 2025.01.02

Handok Affiliate Rezolute's RZ358 Designated as an Orphan Drug by the FDA for the Treatment of Hypoglycemia Due to Tumor-Induced Hyperinsulinism 2024.12.10

Handok Hosts 70th Anniversary R&D Symposium on Open Innovation 2024.10.24

Handok's Affiliate Rezolute Advances Development of Congenital Hyperinsulinism Treatment (RZ358), Confirming Safety and Proceeding with Phase 3 Trials in the U.S. Without Age Restrictions 2024.09.10

Handok's Non-Small Cell Lung Cancer Drug Development Project Selected for Ministry of Trade, Industry and Energy's Global Industry Technology Cooperation Center Program 2024.09.09

Handok's Partner Compass Therapeutics Completes Patient Enrollment for Phase 2/3 Clinical Trial of Bile Duct Cancer Treatment HDB001A (CTX-009) 2024.08.09

Handok Celebrates 70th Anniversary with Publication of 'Handok Archive 70: The Road to Innovation' 2024.07.11